Free Trial

Takeda Pharmaceutical (TAK) Stock Forecast & Price Target

Takeda Pharmaceutical logo
$21.60 +0.18 (+0.82%)
As of 03:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Takeda Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
1
Buy
3

Based on 4 Wall Street analysts who have issued ratings for Takeda Pharmaceutical in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 1 has given a hold rating, 2 have given a buy rating, and 1 has given a strong buy rating for TAK.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TAK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TAK Analyst Ratings Over Time

TypeCurrent Forecast
11/16/25 to 11/16/26
1 Month Ago
10/17/25 to 10/17/26
3 Months Ago
8/18/25 to 8/18/26
1 Year Ago
11/16/24 to 11/16/25
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingBuyModerate BuyHoldHold

TAK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TAK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Takeda Pharmaceutical Stock vs. The Competition

TypeTakeda PharmaceuticalHealthcare CompaniesBroader Market
Consensus Rating Score
3.00
2.32
2.52
Consensus RatingBuyHoldModerate Buy
Predicted UpsideN/A116.51% Upside16.02% Upside
News Sentiment Rating
Neutral News

See Recent TAK News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/3/2026
Weiss Ratings logo
Weiss Ratings
2 of 5 stars
 UpgradeHold (C) ➝ Hold (C+)
10/30/2026
Zacks Research logo
Zacks Research
4 of 5 stars
 UpgradeHold ➝ Strong-Buy
4/8/2026 UpgradeMarket Perform ➝ Outperform
1/13/2026 Initiated CoverageOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:09 PM ET.


Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 11, 2026. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

Takeda Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • Takeda Pharmaceutical Company Limited recently demonstrated strong financial performance by significantly beating analyst expectations in its most recent earnings report, delivering an actual EPS of $0.492 against a consensus estimate of only $0.145, which signals robust profitability and operational efficiency that can drive shareholder value.
  • The company's stock has shown exceptional momentum, reaching a 52-week high of $21.73 and currently trading at $20.85, indicating strong market confidence and upward price trajectory that has outperformed many peers in the pharmaceutical sector over the past year.
  • Analyst sentiment has shifted positively, with recent upgrades from major firms such as Zacks Research raising its rating to "strong-buy" and Wall Street Zen moving to a "buy" rating, reflecting a consensus view that the company's current valuation and growth prospects are attractive for investors.
  • Institutional investors are increasing their exposure to the stock, with funds like Ethic Inc. and Point Nemo Capital LLC adding significant positions in the third quarter, suggesting that professional money managers are identifying undervalued opportunities or strong fundamental drivers in Takeda Pharmaceutical Company Limited.
  • The company maintains a stable dividend yield of 2.28%, providing a consistent income stream for investors while the stock price appreciates, which is particularly appealing for those seeking both growth and yield in their healthcare portfolio.

Takeda Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • There is significant insider selling activity, with executives such as Giles Platford and Andrew Plump selling substantial blocks of shares in recent months, which can signal that company insiders believe the stock is overvalued or that they are diversifying their personal wealth away from the company.
  • Despite earnings growth, there are concerns about cash flow generation, as noted by analysts who point out that operating cash flow has declined to $2.74 billion, suggesting that the reported profits may not be translating into strong underlying cash reserves or liquidity for future investments.
  • The company faces a "generic overhang," meaning that the expiration of patents on key drugs could lead to increased competition from lower-cost generic versions, potentially eroding revenue margins and market share in the future as competitors enter the market.
  • New product launches such as Mimrylo and Orzeyful are ramping up slowly and currently contribute minimally to revenue, creating uncertainty about whether these new therapies will successfully replace the revenue from aging products and drive future growth as expected.
  • The stock's valuation, with a P/E ratio of 27.43, is relatively high compared to some industry peers, which may limit further upside potential if earnings growth slows or if the broader market becomes more risk-averse toward pharmaceutical stocks.

TAK Forecast - Frequently Asked Questions

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There is currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.

According to analysts, Takeda Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Takeda Pharmaceutical's stock had 5 upgrades and 1 downgrade by analysts.

Takeda Pharmaceutical has been rated by research analysts at Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Takeda Pharmaceutical more than other "healthcare" companies. The consensus rating for Takeda Pharmaceutical is Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how TAK compares to other companies.

Brokerages With Takeda Pharmaceutical Recommendations


MarketBeat monitors more than a dozen sources for Takeda Pharmaceutical analyst ratings, with the most recent rating issued on 11/3/2026.
From Our Partners